All In Biotech

Drug Trial Radar · NCT06008119

Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

A Multicenter, Randomized, Open-label, Phase 3 Study to Evaluate the Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 165 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

165

Planned (sponsor's estimate)

Start

Oct 25, 2023

Primary completion

Dec 24, 2026

Study completion Dec 24, 2026

Sponsor

Lead sponsor
Shanghai Kechow Pharma, Inc.Industry
Sponsor type
Industry
First posted
Aug 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, open-label, Phase 3 study

Conditions

  • Colorectal Cancer Metastatic

Interventions

  • Tunlametinib plus VemurafenibDrug

    12mg BID Tunlametinib+720mg BID Vemurafenib

  • Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± CetuximabDrug

    According to investigators' suggestion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS)Time frame: up to 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Oncology Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.